Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Howard, D. N
Right arrow Articles by Cusano, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Howard, D. N
Right arrow Articles by Cusano, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 14, No. 1, 45-49 (2008)
DOI: 10.1177/1078155207085387

Efficacy vs. effectiveness — docetaxel and prednisone in hormone refractory prostate cancer

Diana N Howard, BSc Pharm

Pharmacy department, Tom Baker Cancer Center 1331 - 29 Street N.W. Calgary, Alberta Canada T2N 4N2

Carole Chambers, BSc Pharm MBA

Pharmacy department, Tom Baker Cancer Center 1331 - 29 Street N.W. Calgary, Alberta Canada T2N 4N2, carolech{at}cancerboard.ab.ca

Frances Cusano, BSc Pharm

Pharmacy department, Tom Baker Cancer Center 1331 - 29 Street N.W. Calgary, Alberta Canada T2N 4N2

Objectives. To assess the clinical effectiveness of docetaxel and prednisone in a clinical setting and to compare the results to those seen in the pivotal clinical trial. To assess the impact of various factors on the prognosis of patients treated with docetaxel.

Design. Retrospective chart review. The primary outcome measured was survival. Survival data was analyzed through the Kaplan—Meier methodology. A multivariate analysis of prognostic variables was also conducted.

Setting. Public cancer centers within the Canadian province of Alberta.

Patients. Hormone refractory, metastatic prostate cancer patients initiated on docetaxel chemotherapy between September 2004 and February 2007 within the Alberta Cancer Board.

Main Outcome Measured. The primary outcome measured was median survival.

Results. Among 161 patients eligible for review, median survival was 17.22 months. Chemotherapy received after docetaxel was determined to be a significant favorable prognostic factor for survival ( p<0.0001).

Conclusion. In a clinical setting, docetaxel and prednisone did not perform as well in terms of median survival, as it was shown to in prior clinical trials (17.22 vs. 18.9 months). Further investigation into the impact of docetaxel and prednisone on quality of life in clinical practice, would complement the findings of this study. J Oncol Pharm Practice (2008) 14: 45—49.

Key Words: effectiveness • docetaxel • prostate cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?